Leuplin DPS

ApprovedSmall molecule

JJin Soon Hwang

Leuplin DPS is one of 13 small molecule programs targeting Central precocious puberty. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Central Precocious PubertyActive, not recruiting

Central Precocious PubertyApproved

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Central Precocious Puberty

#DrugCompanyPhaseTrials

Lupron

AbbVie

Approved

1 2

Megace

Bristol-Myers Squibb

Approved

1 3

Leuprorelin

Takeda

Approved

3 4

Lupron

EEastern Cooperative Oncology Group

Phase 3

3 5

Trelstar

OOncoVerity, Inc.

Phase 3

1 6

Triptorelin Pamoate

Ipsen

Phase 3

2 7

Debio 025

DDebiopharm International SA

Phase 3

1 8

Supprelin La

UUniversity of Hertfordshire

Phase 3

1 9

Eligard

HHanAll BioPharma Co., Ltd.

Leuplin DPS

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Central precocious puberty1 trial

Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty

Completed·JJin Soon Hwang·Phase 4·NCT03316482·58 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Leuplin DPS. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Leuplin DPS compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Leuplin DPS. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jin Soon Hwang company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: JJin Soon Hwang

Leuplin DPS

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Central precocious puberty1 trial

References

Drug Info

Quick Facts

Related News